These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 26363365)

  • 21. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
    Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
    Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
    Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    Broicher SD; Filli L; Geisseler O; Germann N; Zörner B; Brugger P; Linnebank M
    J Neurol; 2018 May; 265(5):1016-1025. PubMed ID: 29464379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A guide to treating gait impairment with prolonged-release fampridine (Fampyra
    Ramió-Torrentà L; Álvarez-Cermeño JC; Arroyo R; Casanova-Estruch B; Fernández O; García-Merino JA; Hernández MA; Izquierdo G; Martínez-Yélamos S; Meca J; Moral E; Olascoaga J; Prieto JM; Saiz A
    Neurologia (Engl Ed); 2018 Jun; 33(5):327-337. PubMed ID: 26873645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study.
    Mitsikostas DD; Doskas T; Gkatzonis S; Fakas N; Maltezou M; Papadopoulos D; Gourgioti R; Mitsias P
    Adv Ther; 2021 Mar; 38(3):1536-1551. PubMed ID: 33528792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI; Sobieraj DM; Marinucci LN
    Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
    Sayao AL; Bueno AM; Devonshire V; Tremlett H;
    Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
    Mathiesen HK; Sorensen PS
    Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC; Ruiz JA; Koenig CM; Anderson BM; Olson KM; Triche EW
    J Neurol Sci; 2015 Sep; 356(1-2):77-82. PubMed ID: 26139339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
    Fernandez O; Berger T; Hartung HP; Putzki N
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with fampridine in clinical practice: analysis of a possible marker of clinical response.
    Alvarez-Payero M; Valeiras-Muñoz C; Lion-Vázquez S; Piñeiro-Corrales G; Muñoz-García D; Midaglia L
    Int J Neurosci; 2017 Oct; 127(10):915-922. PubMed ID: 28054826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of fampridine on axonal excitability in multiple sclerosis.
    Huynh W; Pickering H; Howells J; Murray J; Cormack C; Lin CS; Vucic S; Kiernan MC; Krishnan AV
    Clin Neurophysiol; 2016 Jul; 127(7):2636-42. PubMed ID: 27291883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
    Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Barreira AA; Brooks JB; Claudino R; Correa EC; Ferreira ML; Finkelsztejn A; Finkelsztejn J; da Gama PD; Goncalves MV; Guerreiro CT; da Cunha Matta AP; Marques VD; Rizo Morales R; Parolin MF; de Castro Ribeiro M; Ribeiro TA; Ruocco HH; Sato H; Scherpenhuijzen S; Siquineli F; de Carvalho Sousa NA; Varela DL; Tauil CB; Winckler TC
    NeuroRehabilitation; 2016 Jun; 39(2):301-4. PubMed ID: 27372365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.
    Rodriguez-Leal FA; Haase R; Akgün K; Eisele J; Proschmann U; Schultheiss T; Kern R; Ziemssen T
    Ther Adv Chronic Dis; 2019; 10():2040622319835136. PubMed ID: 31037211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalfampridine effects on cognition, fatigue, and dexterity.
    Korsen M; Kunz R; Schminke U; Runge U; Kohlmann T; Dressel A
    Brain Behav; 2017 Jan; 7(1):e00559. PubMed ID: 28127507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cross-sectional comparison of performance, neurophysiological and MRI outcomes of responders and non-responders to fampridine treatment in multiple sclerosis - An explorative study.
    Mamoei S; Jensen HB; Dalgas U; Zijdewind I; Pedersen AK; Nygaard MKE; Eskildsen SF; Stenager E
    J Clin Neurosci; 2020 Dec; 82(Pt A):179-185. PubMed ID: 33317729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL; Sidovar MF; Coleman CI
    Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
    J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.